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Highlights 
 
 Vascular white matter lesions (WML) reduce brain metastases (BM) in patients with 
lung cancer 
 
 If presence of WML negatively affects number of BM in melanoma is unknown 
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 Degree of WML was higher in BM negative patients with melanoma  
 
 Vascular risk factors were more frequent in BM negative patients 
 
 WML appear to reduce BM in different tumor types.  
 
 
 
 
Abstract 
Objectives: Brain metastasis (BM) is a major complication of different cancers. There is 
increasing evidence for influence of vascular factors on BM in patients with non-small cell 
lung cancer (NSCLC). It is not known if the same is true for other tumors that might rely on 
different forms of vasculogenesis. The objective of this retrospective study was to evaluate a 
possible negative association of vascular white matter lesions and vascular risk factors 
(vasRF) with brain metastases in patients with melanoma. Patients and Methods: 3D-brain 
magnetic resonance imaging (MRI) of 30 patients with brain metastases (BM) from 
malignant melanoma and screening MRI of 31 BM negative patients were analysed. Number 
of metastases was calculated and T2 hyperintensive white matter lesions (WML) were 
classified according to Fazekas-Score (grade I-III) per patient and compared between BM+ 
and BM- patients. Results: Patients without BM showed more pronounced WML (median = 
WML 1, mean = 1.3; SD = 1.04,) than patients with BM (median=WML 0, mean = 0.6; SD = 
0.8, p=0.017). With respect to vascular risk factors, brain metastases were more likely (px2 = 
0.019) in patients without vasRF. Conclusions: White matter lesions and possibly vascular 
risk factors may reduce the risk of brain metastases in different malignant tumors including 
melanoma. Presence of WML in patients with brain metastases could potentially influence 
treatment choice regarding local or whole brain treatment after further multicentric 
prospective validation. 
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Introduction: 
Cerebral metastases are severe complications in patients with cancer. They occur in up to 40% 
of patients with solid tumors [1]. According to diagnosis specific graded prognostic 
assessment (DS-GPA) number of brain metastases has prognostic impact in several tumors 
(lung cancer, melanoma, renal cell cancer) [2]. In addition, number of brain metastases is 
highly relevant for decision between local and whole brain treatment [1,3,4]. Interestingly, 
factors that determine metastasis number are poorly described. Systemic tumor control and 
CNS-proneness of tumor cells are major determinants [5,6,7].  However, blood supply is also 
of relevance in brain metastasis.  Most metastases develop in well perfused areas (e.g. the 
border of white and grey matter) while worse perfused areas (e.g. deep white matter) appear 
protected from metastases [8]. In addition, there is increasing evidence that microvascular 
damage in the brain (cerebral microangiopathy) that leads to white matter lesions (WML) in 
cerebral MRI can reduce number of BM in malignant disease e.g. in non-small cell lung 
cancer (NSCLC) [9, 10]. In the present retrospective analysis the influence of white mater 
lesions and vascular risk factors on number of brain metastases was analyzed for patients with 
diagnosed melanoma.  
 
Material and Methods: 
Charts of all patients diagnosed with "malignant melanoma" (MM) that presented at the 
University Hospital Leipzig from October 2004 – January 2015 were retrospectively filtered.  
Patients with malignant melanoma were included. One group of patients that developed BM 
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
 
from melanoma was included as the “case” group at time of diagnosis of BM. A second group 
of patient was included as “control” group if 1) advanced melanoma with at least AJCC stage 
III at initial diagnosis was present and 2) if regular 3 monthly cerebral MRI was available 
with a follow up period of at least 3 years. Of patients of both groups a) complete clinical 
charts with medical history and age and b) 3 tesla cerebral MRI with 3D T1-weighted 
sequence after contrast agent injection (slice thickness of 1–1.5 mm) and T2/FLAIR sequence 
at diagnosis of brain metastasis or as regular screening needed to be available. Presence of 
vascular risk factors (arterial hypertension (AH), diabetes mellitus (DM), 
hypercholesterolemia (HC) and smoking were retrospectively compiled on basis of medical 
files. For diagnosis of AH patients needed to receive anti-hypertensive medication at time of 
documentation. Patients with DM, hypercholesterolemia and PAOD could be with or without 
pharmacological treatment. Smokers and Ex-smokers that stopped smoking ≤ 5 years before 
presentation were defined as smokers. 
 
MRI analysis  
Pre-treatment MR axial 3D T1-weighted images of the brain of the included patients were 
retrospectively analyzed by SN and BAB under the supervision of CS (with more than 7 years 
experience in clinical neuroradiology). Number and diameter of all metastases were 
determined blinded for presence of vascular risk factors. In addition, presence and degree of 
cerebral small vessel disease (also called white matter lesions (WML) was determined with 
the Fazekas score [11].  In Fig. 1 examples of grades of WML according to Fazekas Score are 
displayed 
 
Written informed consent regarding scientific use of anonymized medical data was received 
from all patients at initial presentation in our department. 
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Statistical analysis  
Type and number of vascular risk factors and stage of white matter lesions (WML 0-III) were 
compared between patients with and without BM. IBM SPSS V23.0 was applied for statistical 
analysis. Normal distribution of continuous variable was tested using the Kolmogorov–
Smirnov test [12]. As data was not normally distributed (p = 0.001) statistical evaluation was 
performed with Mann-Whitney-U-Test (Ngroup = 2) or multiple Independent-Samples Kruskal-
Wallis-Test (Ngroup > 2) [12]. Statistical significance was accepted at p < 0.05. Univariate 
(UVA) and multivariate data analyses (MVA) [14] were used. Evaluation or interaction of 
more than one vascular risk factor was possible in multivariate analyses. One MVA was 
conducted by recoding the categorical subtypes (S, AH, DM, HC) based on clinical history 
into positive or negative status (0, 1) and another by amount of vascular risk factors per 
investigation period (0, > 1 to 4). By using Pearson’s Chi square test of Independence (p χ2), 
comparisons between different categorical variables were made and associations identified. 
Interactions of categorical variables were further explored by using logistic regression under 
description of odds ratio and estimation via the maximum-likelihood method. Figures were 
assembled with IBM SPSS V23.0 and Microsoft Office 365, Version 2017. 
 
 
Results:  
Patient characteristics (Table 1)  
Overall, 61 patients fulfilled the inclusion criteria for this analysis, 30 patients with BM and 
31 patients without BM. Median initial AJCC tumor stage was not different (stage 3) between 
both groups (p=0.339). At time of analysis, about 50% of all patients were pre-treated with 
immune - and/or chemotherapy, without significant differences between the two groups 
(p=0.332). Follow up time from initial diagnosis appeared somewhat higher (mean: 70.9 
months vs. 58.6 months, median: 36.5 months vs. 32.5 months) in patients with BM but was 
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not significantly different (p=0.686). Median patient age was significantly higher in patients 
with BM (72 years vs. 62 years, p = 0.029). BM positive patients were more frequently male 
(70% vs. 58%, p=0.373) without reaching significance.  
 
Vascular risk factors (Table 1) 
Within both patient cohorts 42 patients (68.9 %) had a clinical history of vascular risk factors 
(smoking (n = 9; 14.8 %), diabetes mellitus (n = 9; 14.8 %), hypercholesterolemia (n = 10; 
16.4 %), systemic hypertension (n = 35; 57.4 %). Between BM+ and BM- group the 
frequency of AH (50% vs. 64%, p=0.252) and smoking (13% vs. 16%, p=0.758) was not 
significantly different. There was a trend for more patients with DM (23% vs. 7%, p=0.080) 
and significant more patients with HC (29% vs. 3%, p=0.007) in BM- patients.  
In total, 80% of patients without BM had at least one vascular risk factor while only 56% of 
patients with BM had at least one vascular risk factor in their medical charts (p=0.019). The 
number of vascular risk factor was significantly higher in patients without (mean N = 1.3; 
p=0.019) than with BM (mean N = 0.7), Fig. 2. 
 
Monovariate logistic regression modelling of each vascular risk factor with the BM status 
confirmed no significant interaction as above (AH: b= -0.598, Exp (B) = 0.550 : 1, df = 1, p= 
0.254; S: b= -0.223, Exp (B) = 0.8 : 1, df = 1, p= 0.759; DM: b= -1,407, Exp (B) = 0.245 : 1, 
df = 1, p= 0.097), except of hypercholesterolemia (b= -2473, Exp (B) = 0.084 : 1, df = 1, p= 
0.023).  
 
In multivariate analysis, across BM+ and BM- group, vascular  risk  factor  status  appeared  
being associated  with  BM  status  (χ2(1)  = 4.087, px2 = 0.043, r = -0.259). In logistic 
regression, BM status was explored on interaction with vascular risk factor status. The chance 
for patient with brain metastasis being positive for vascular risk factors was significantly 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
reduced (b= -1,159, Exp (B) = 0.314 : 1, df = 1, p= 0.048). Similar, the amount of vascular 
risk factors was found being negatively related to brain metastasis (χ2(4) = 6.098, p x2 = 
0.019, r = -0.308). In further logistic regression modelling, the unspecified amount of vascular 
risk factors (1-4) supported the suspected negative interaction with the brain metastasis status 
(b= -0.721, Exp (B) = 0.486 : 1, df = 1, p= 0.022). 
 
 
Frequency of white matter lesions  
Overall, 25 (41 %) patients had no white matter lesions (WML0), while 16 (26.2 %) showed 
punctate foci (WML1), 16 patients (26.2 %) had confluent foci (WML2) and 4 cases (6.6%) 
large confluent areas were noted (WML3); (Fig. 3A).WML were significantly more frequent 
and severe in patients without BM (median WML 1, mean = 1.3; SD = 1.04,) compared to 
patients with BM (median WML0, mean = 0.6; SD = 0.8, p = 0.017); (Fig. 3B). 
 
Correlation of brain metastasis and white matter lesions 
Significant  inverse  correlation  between  brain  metastasis  and  WML  was  identified  by 
Pearson’s Chi square test of Independence (χ2(3) = 6.945; p χ2 = 0.03; r =-0.337). The higher 
the WML grade, the significant less brain metastases (p = 0.017), (Fig. 4).  The overall 
suspected negative correlation was support in multinomial logistic regression modelling (b= -
0.721, Exp (B) = 0.486 : 1, df = 1, p= 0.015). 
 
Discussion: 
There is increasing evidence that cerebral small vessel disease (represented by WML) can 
reduce number of brain metastases. However, most of this evidence is derived from patients 
with NSCLC (9, 10).  It is not known, if this mechanism is also important in other tumor 
types. Potentially, different types of tumor can use distinct pathways of vasculogenesis 
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(15,16). Hence the relevance of “host” vessels might be different in other tumors e.g. in 
malignant melanoma. 
In the present retrospective analysis patients with advanced stage melanoma that did not 
develop brain metastases in course of their disease had significantly more signs of cerebral 
microangiopathy on cerebral MRI. In addition there appeared an inverse correlation of degree 
of WML and brain metastases. These findings are coherent with the results from NSCLC and 
indicate that cerebral small vessel disease can reduce incidence of brain metastasis or prolong 
time to onset in different tumor types.  
Small vessel disease of the brain is characterized by histopathological changes, such as loss of 
structure in arteriolar walls, narrowing of the vessels lumen and thickening of the vessels 
walls [17-20]. WML are common in patients with vascular risk factors like arterial 
hypertension [21] and are associated with strokes, dementia and intracerebral bleeding (ICB) 
[22-24].  For the process of brain metastasis embolization of cancer cells to cerebral vessels is 
essential. It occurs early in the multi-step process of cerebral metastasation [25]. 
Subsequently, endothelial factors contribute to successful seeding of tumor cells to and 
growth in the brain [26]. Carbonell et al. [6] described a β1-integrin mediated active 
interaction of the basement membrane of cerebral blood vessels with circulating tumor cells 
as a requirement for tumor cell adhesion and development of brain metastasis. In addition, 
deficiencies of endothelial proteins can reduce metastatic ability of adjacent tumor cells [27]. 
From this it can be hypothesized that levels of functional proteins like that of integrins are 
decreased in small vessel disease of the brain and ability for metastasis formation in the brain 
is reduced. However, there is only indirect experimental evidence for this e.g. from a rare 
inherited vasculopathy (cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy, CADASIL), in which levels of integrins (incl. β1-subtypes) are 
generally decreased [28]. Propably, cancers with proneness to CNS (NSCLC, SCLC, 
melanoma) that rely on co-option of physiological pre-existing vessels [29] are more 
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influenced by small vessel disease/WML than tumors that predominantly perform neo-
angiogenesis (e.g. renal cell carcinoma [29].  
If vascular risk factors can also affect brain metastasis is less clear from the literature. One 
clinical study demonstrated that an alteration of vascular architecture occurring in long-
standing diabetes mellitus patients could be a protective factor against metastases from lung 
cancer [30].  However, in a recent retrospective first screening approach a general protective 
effect of vascular risk factors against BM across several tumor types was not detectable [31]. 
In the present analysis restricted to melanoma vascular risk factors were somewhat more 
frequent in patients without BM. This could point to a possible influence but is a very weak 
indication and needs to be validated in a larger cohort of patients with objectively measured 
vascular risk factors and reported co-medication. 
Our analysis is restricted by its small size and monocentric, retrospective nature not fully 
excluding sampling bias. There was significant imbalance of patient age between the two 
groups with younger patients in the group without brain metastases. This could be relevant as 
patient age itself is a vascular risk factor and could influence results. However, in a larger 
earlier analysis of 200 patients, patient age was not associated with number of brain 
metastases [32]. In addition, a higher patient age in the group of patients without BM would 
be expected if age was relevant as a vascular risk factor and as an important confounder. The 
opposite was the case in the present study, which might strengthen the results. Regarding 
possible selection bias, median follow up time from diagnosis appeared 4 months 
(approximately 10%) longer in BM+ patients. This could reflect increasing BM risk with 
increasing duration of disease. However, with a p-value of 0.686 in comparison between the 
two groups a significant effect of this difference on present results appears not likely. 
In conclusion, our analysis indicates a protective effect of small vessel disease in the brain 
against BM in melanoma. Presence of WML in patients with brain metastases could 
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potentially influence treatment choice regarding local or whole brain treatment after further 
multicentric prospective validation. 
 
Funding : 
This work did not receive any funding 
 
Conflict of Interest: 
The authors declare that there is no conflict of interest 
 
Ethical approval: 
All procedures performed in studies involving human participants were in accordance with 
the ethical standards of the institutional research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards 
 
Informed consent: 
Written informed consent regarding scientific use of anonymized medical data was received 
from all patients at initial presentation in our department. 
 
Acknowledgements: 
B.A.B was recipient of a merit-based doctoral scholarship from the Hans-Böckler  Foundation 
funded by the Federal  Ministry  of  Education  and  Research  –  Germany (BMBF). 
 
 
References:  
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
1. Soffietti R, Ruda R, Mutani R (2002) Management of brain metastases. Journal of 
Neurology 249(10):1357–69 
2. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, 
Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, 
Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2011) Summary 
report on the graded prognostic assessment: an accurate and facile diagnosis-specific 
tool to estimate survival for patients with brain metastases. J Clin Oncol 1;30(4):419-
25 
3. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, 
multiplicity, surgery, and survival. Cancer 78(8):1781–8 
4. Patil CG, Pricola K, Garg SK, Bryant A, Black KL (2010) Whole brain radiation 
therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain 
metastases. Cochrane database Syst Review (6):CD006121 
5. Ellis TL, Neal MT, Chan MD (2012) The role of surgery, radiosurgery and whole 
brain radiation therapy in the management of patients with metastatic brain tumors. 
International Journal of Surgical Oncology 2012:952345 
6. Carbonell WS, Ansorge O, Sibson N, Muschel R (2009) The vascular basement 
membrane as “soil” in brain metastasis. PLoS One 4(6):e5857 
7. Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter KC, Pezzella F 
(2013) Vessel co-option in primary human tumors and metastases: an obstacle to 
effective anti-angiogenic treatment? Cancer Med 2(4):427–36  
8. Seidel C, Hambsch P, Hering K, Bresch A, Rohde S, Kortmann RD, Gaudino C 
(2015) Analysis of frequency of deep white matter metastasis on cerebral MRI. J 
Neurooncol 123(1):135-9 
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
9. Mazzone PJ, Marchi N, Fazio V, Taylor JM, Masaryk T, Bury L, Mekhail T, Janigro 
D (2009) Small Vessel Ischemic Disease of the Brain and Brain Metastases in Lung 
Cancer Patients. PLoS One 4(9): e7242 
10. Hayashi N, Mitsuya K, Nakasu Y, Naito T, Ohka F, Takahashi T. Negative impact of 
leukoaraiosis on the incidence of brain metastases in patients with lung cancer. J 
Neurooncol 2017; Jul 27. doi: 10.1007/s11060-017-2574-x. [Epub ahead of print] 
PubMed PMID: 28752500. 
11. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal 
abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J 
Roentgenol 149(2):351–6 
12. Ebermann E (2016) Kolmogorov-Smirnov-Test mit SPSS. 
https://www.univie.ac.at/ksa/elearning/cp/quantitative/quantitative-62.html Accessed 
15 May 2016 
13. Bühl, Achim (2014) SPSS 22: Einführung in die moderne Datenanalyse (Pearson 
Studium - Scientific Tools). 14th edn. Pearson Deutschland GmbH, Hallbergmoos, 
Germany 
14. Johnson, RA, Wichern, Dean W (2007) Applied Multivariate Statistical Analysis. 6th 
edn. Pearson Education Limited, Essex 
15. Carmeliet P, Rakesh KJ (2011) Molecular mechanisms and clinical application of 
angiogenesis. Nature 473(7347): 298–307 
16. Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Hackl M, Widhalm G, 
Hainfellner JA, Dieckmann K, Pichler J, Hutterer M, Melchardt T, Bartsch R, 
Zielinski CC, Birner P, Preusser M (2015) Differential role of angiogenesis and tumor 
cell proliferation in brain metastases according to primary tumor type: analysis of 639 
cases. Neuropathol Appl Neurobiol 41(2):e41-55 
AC
CE
PT
ED
 M
AN
US
CR
IPT
13 
 
17. Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol 9: 689–701 
18. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, 
Geurts JJ (2011) Heterogeneity of small vessel disease: a systematic review of MRI 
and histopathology correlations. J Neurol Neurosurg Psychiatr 82: 126–135 
19. Brown WR, Thore CR (2011) Review: cerebral microvascular pathology in ageing and 
neurodegeneration. Neuropathol Appl Neurobiol 37(1):56–74  
20. Okroglic S, Widmann CN, Urbach H, Scheltens P, Heneka MT (2013) Clinical 
symptoms and risk factors in cerebral microangiopathy patients. PLoS One 
8(2):e53455 
21. Spolveri S, Baruffi MC, Cappelletti C, Semerano F, Rossi S, Pracucci G, Inzitari D 
(1998) Vascular risk factors linked to multiple lacunar infarcts. Cerebrovasc Dis 
8(3):152–157  
22. Brown WR, Moody DM, Thore CR, Anstrom JA, Challa VR (2009) Microvascular 
changes in the white mater in dementia. J Neurol Sci 283(1–2):28–31 
23. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van 
Harskamp F, Tanghe HL, de Jong PT, van Gijn J, et al. (1994) Cerebral white matter 
lesions, vascular risk factors, and cognitive function in a population-based study: the 
Rotterdam Study. Neurology 44: 1246–1252 
24. Sato S, Delcourt C, Heeley E, Arima H, Zhang S, Al-Shahi Salman R, Stapf C, Woo 
D, Flaherty ML, Vagal A, Levi C, Davies L, Wang J, Robinson T, Lavados PM, 
Lindley RI, Chalmers J, Anderson CS (2016) Significance of Cerebral Small-Vessel 
Disease in Acute Intracerebral Hemorrhage. Investigators Stroke 47(3):7017 
25. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. 
J Neurooncol 75(1):5–14 
AC
CE
PT
ED
 M
AN
US
CR
IPT
14 
 
26. Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D (2017) Factors involved in cancer 
metastasis: a better understanding to "seed and soil" hypothesis. Mol Cancer 16(1):176  
27. Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, Tian YM, 
Lanahan AA, Pollard P, de Almodovar CR, De Smet F, Vinckier S, Aragonés J, 
Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, 
Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P. (2009) Heterozygous 
deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial 
normalization. Cell 136(5):839-851 
28. Dziewulska D, Nycz E Disturbed integrin expression in the vascular media in 
CADASIL (2016) Folia Neuropathol 54(4):375-381 
29. Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, et al. (2013) Vessel 
co-option in primary human tumors and metastases: an obstacle to effective anti-
angiogenic treatment? Cancer Med 2(4):427–36 
30. Hanbali A, Al-Khasawneh K, Cole-Johnson C, Divine G, Ali H  (2007) Protective 
effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch 
Intern Med 167(5):513 
31. Nagel S, Berk BA, Kortmann RD, Hoffmann KT, Seidel C (2018) Can vascular risk 
factors influence number and size of cerebral metastases? A 3D-MRI study in patients 
with different tumor entities. Clin Neurol Neurosurg (165):55-59 doi: 10.1016 
32. Berk BA, Nagel S, Hering K, Paschke S, Hoffmann KT, Kortmann RD, Gaudino C, 
Seidel C (2016) White matter lesions reduce number of brain metastases in different 
cancers: a high-resolution MRI study. J Neurooncol 130(1):203-209  
 
 
 
AC
CE
PT
ED
MA
NU
SC
RI
PT
15 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE CAPTIONS  
Figure 1  – WML Staging according to Fazekas Score  
A = Stage I: individual hyperintensities in white matter and periventricular regions 
B = Stage II: beginning confluent hyperintensities in white matter and periventricular regions  
C = Stage III: heavy confluent hyperintensities in white matter and periventricular regions  
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Figure 2  – WML Grade distribution on axial T2/FLAIR MRI based on brain metastasis 
A) Bar chart on the absolute amount of patients with different WML grades grouped by 
BM occurrence   
B) Boxplot of WML Fazekas Scoring by Brain Metastasis (Box = interquartile range 
(IQR), horizontal line = median, whiskers = max 1.5xIQR, N=number of patients) 
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Figure 3 – Influence of WML on brain metastasis: Absolute number of patients with 
different WML grades illustrated as bars chart by brain metastases.  
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Figure 4 – Vascular risk factors and brain metastasis: Mean number of vascular risk factor  
according to brain metastasis. Data are displayed as boxplots (Box = interquartile range 
(IQR), horizontal line = median, whiskers = max 1.5xIQR, N=number of vascular risk 
factors). 
 
 
 
 
 
 
 
Table 1 – Patients Characteristics:  
At time of analysis, about 50% of all patients were pre-treated with immune - and/or 
chemotherapy, without significant differences between the two groups (p=0.332). 
Between BM+ and BM- group the frequency of AH (50% vs. 64%, p=0.252) and smoking 
(13% vs. 16%, p=0.758) was not significantly different. There was a tendency for more 
patients with DM (23% vs. 7%, p=0.080) and with HC (29% vs. 3%, p=0.007) in BM- 
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patients. In total, 80% of BM- patients had at least one vascular risk factor while only 56% of 
patients with BM had a vascular risk factor in their medical charts. The number of vascular 
risk factor was significantly higher in patients without (mean N = 1.3; p=0.019) than with BM 
(mean N = 0.7).  
 
 
Table 1 
PATIENT 
CHARACTERISTICS 
BM + (N=30) BM- (N=31) p-Value 
MEAN  
SD 
MEDIAN MEAN  
SD 
MEDIAN BM+ vs. BM- 
Patient age 71.8  
12.5 
75 60.63 
13.4 
62 0.029* 
Time from primary tumor 
diagnosis in months 
70.89  
100.4 
36.45 58.6 
57.8 
32.5 0.686 
Median initial AJCC- 
Tumor stage 
3 3 0.339 
Prior 
medical 
therapy 
No therapy 14/30 (46%) 18/31 (58%) 0.373 
Immuno- and /or 
Chemotherapy 
16/30 (53%) 13/31 (42%) 
Gender (m =male, f =female) m: 70%, f: 30% m: 58%, f: 42% 0.332 
Patients with AH (%) 15/30 (50%) 20/31 (64%) 0.252 
Patients Smoking (%) 4/30 (13%) 5/31(16%) 0.758 
Patients with DM (%) 2/30 (7%) 7/31 (23%) 0.080 
Patients with 
Hypercholesterolemia (%) 
1/30 (3%) 9/31 (29%) 0.007 
Cumulated Patients with 
vascular risk factors (%) 
56% 80%  0.019* 
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